CL2022001172A1 - Forma amorfa de un receptor del componente c5a del complemento - Google Patents

Forma amorfa de un receptor del componente c5a del complemento

Info

Publication number
CL2022001172A1
CL2022001172A1 CL2022001172A CL2022001172A CL2022001172A1 CL 2022001172 A1 CL2022001172 A1 CL 2022001172A1 CL 2022001172 A CL2022001172 A CL 2022001172A CL 2022001172 A CL2022001172 A CL 2022001172A CL 2022001172 A1 CL2022001172 A1 CL 2022001172A1
Authority
CL
Chile
Prior art keywords
amorphous form
receptor
complement component
compound
complement
Prior art date
Application number
CL2022001172A
Other languages
English (en)
Inventor
Yibin Zeng
Penglie Zhang
Manmohan Reddy Leleti
Kwok Yau
Kenken Luong
Rajinder Singh
Rebecca M Lui
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of CL2022001172A1 publication Critical patent/CL2022001172A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Secondary Cells (AREA)
  • Soft Magnetic Materials (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Se proporciona una forma amorfa de un receptor del componente 5a del complemento teniendo la fórmula del Compuesto 1. También se proporcionan composiciones farmacéuticas y métodos de tratamiento usando la forma amorfa del Compuesto 1.
CL2022001172A 2019-11-08 2022-05-04 Forma amorfa de un receptor del componente c5a del complemento CL2022001172A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962932644P 2019-11-08 2019-11-08

Publications (1)

Publication Number Publication Date
CL2022001172A1 true CL2022001172A1 (es) 2023-02-17

Family

ID=75846408

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001172A CL2022001172A1 (es) 2019-11-08 2022-05-04 Forma amorfa de un receptor del componente c5a del complemento

Country Status (14)

Country Link
US (1) US11603356B2 (es)
EP (1) EP4054576A4 (es)
JP (1) JP2023501789A (es)
KR (1) KR20220098754A (es)
CN (1) CN114641288A (es)
AU (1) AU2020378397A1 (es)
BR (1) BR112022007489A2 (es)
CA (1) CA3155542A1 (es)
CL (1) CL2022001172A1 (es)
IL (1) IL292383A (es)
MX (1) MX2022005406A (es)
TW (1) TW202128622A (es)
WO (1) WO2021092286A1 (es)
ZA (1) ZA202305624B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202128623A (zh) 2019-11-08 2021-08-01 美商卡默森屈有限公司 補體成分Ｃ５ａ受體之鹽形式
WO2022078269A1 (zh) * 2020-10-16 2022-04-21 苏州科睿思制药有限公司 Avacopan的晶型及其制备方法和用途
EP4137133A1 (en) 2021-08-19 2023-02-22 Sandoz AG Crystalline form of avacopan
WO2022263263A1 (en) 2021-06-16 2022-12-22 Sandoz Ag Crystalline form of avacopan

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005289635A1 (en) * 2004-09-27 2006-04-06 Acadia Pharmaceuticals Inc. Salts of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide and their preparation
SG172338A1 (en) 2008-12-22 2011-07-28 Chemocentryx Inc C5ar antagonists
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
SI2585064T1 (sl) 2010-06-24 2017-08-31 Chemocentryx, Inc. Antagonisti C5AR
ES2926828T3 (es) 2014-09-29 2022-10-28 Chemocentryx Inc Procesos e intermedios en la preparación de antagonistas de C5aR
WO2019089534A1 (en) 2017-10-31 2019-05-09 Chemocentryx, Inc. C5aR INHIBITOR REDUCTION OF URINARY sCD163
EP3801519A4 (en) 2018-06-07 2022-03-30 ChemoCentryx, Inc. DOSAGE AND EFFECT OF A C5A ANTAGONIST IN ANCA-ASSOCIATED VASCULITIS
CN113784955A (zh) 2019-03-11 2021-12-10 因弗拉克斯有限责任公司 作为C5a受体调节剂的稠合哌啶基双环和相关化合物
KR20220098179A (ko) 2019-11-08 2022-07-11 케모센트릭스, 인크. 보체 성분 C5a 수용체의 유리 염기 결정질 형태
TW202128623A (zh) 2019-11-08 2021-08-01 美商卡默森屈有限公司 補體成分Ｃ５ａ受體之鹽形式

Also Published As

Publication number Publication date
KR20220098754A (ko) 2022-07-12
EP4054576A4 (en) 2023-12-13
BR112022007489A2 (pt) 2022-07-12
AU2020378397A1 (en) 2022-06-23
WO2021092286A1 (en) 2021-05-14
MX2022005406A (es) 2022-05-24
JP2023501789A (ja) 2023-01-19
CN114641288A (zh) 2022-06-17
IL292383A (en) 2022-06-01
US11603356B2 (en) 2023-03-14
ZA202305624B (en) 2023-12-20
EP4054576A1 (en) 2022-09-14
US20210139426A1 (en) 2021-05-13
TW202128622A (zh) 2021-08-01
CA3155542A1 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
CL2022001172A1 (es) Forma amorfa de un receptor del componente c5a del complemento
CL2022001173A1 (es) Forma cristalina de la base libre de un receptor del componente c5a del complemento
CY1122046T1 (el) Δικυκλικα ετεροκυκλικα παραγωγα ως αναστολεις βρομοτομεων
UY37710A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
CO2018000660A2 (es) Compuestos derivados del (3β)-cholest-5-en-3-alquil-3-ol y (3β)-cholest-3-alquil-3-ol
CY1123025T1 (el) Αναστολεις βρωμοεπικρατειας
GEP20237506B (en) Pcsk9 antagonist compounds
EA202092490A1 (ru) Модуляторы метилмодифицирующих ферментов, композиции и их применения
PH12018500061A1 (en) Oxysterols and methods of use thereof
EA201791955A1 (ru) ИНГИБИТОРЫ TGF-β
EA201650031A1 (ru) Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1
CL2018001199A1 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
EA202191519A1 (ru) Модуляторы trex1
CO2021000932A2 (es) Forma cristalina de compuesto profármaco de lanosterol y aplicación de la misma
SV2017005381A (es) Compuestos de imidazopiridazina
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
MX2020004810A (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas.
ZA202204442B (en) Salt forms of a complement component c5a receptor
EA201792594A1 (ru) Положительные аллостерические модуляторы мусаринового рецептора м1
EA201890684A1 (ru) Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1
MX2021007258A (es) Composiciones de esparsentan amorfas.
CL2022000802A1 (es) Compuestos heterocíclicos de arilmetileno como bloqueadores del canal shaker de potasio kv1.3
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias